LSU Health NEW ORLEANS
Institutional Biosafety Committee

LSU HSC-New Orleans Institutional Biosafety Committee
Meeting Minutes

Date: Wednesday, July 9, 2025
Time: 1:00 PM- 2:06 PM
Location: Zoom

Members present:
1. Zea, *IBC Chair*
2. Didier Mejia, *BSO*
3. Birke, *Animal Containment*
4. Boulares
5. Wang
6. Yue
7. Zabaleta
8. Curran, *Local Non-affiliated Member*

Members excused:
1. Catling, *IBC Vice Chair*
2. Guidry, *Local Non-affiliated Member*

Other Individuals in Attendance:
1. Landry, *IBC/IACUC Coordinator*
2. Fuselier, *IBC/IACUC Specialist*

1:01pm **Quorum Present**
The IBC has 11 voting members and 6 are required to conduct business

1:06pm **Call to Order**
The IBC Chair called the meeting to order

1:06pm **Conflicts of Interest**
The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.

1:07pm **Review and approval of previous meeting minutes**
- June 11, 2025

A motion was made and seconded to approve the minutes as written. Motion carried.
These minutes were posted on the ORS IBC webpage.

1:10pm **Review of Prior Business**
- New Committee Member

The Committee discussed the need to fill a vacant member position. Following the review of candidate nominations, a vote was conducted, and Dr. Robert Siggins was appointed to the committee.

1:12pm **New Business**
None

1:12pm **Review of Incidents & Non-compliance**
- **Administrative Closures Due to Inactivity from June 11 to July 9, 2025**

N/A

- **Protocols that are suspended, in "Grace Period" and destined for administrative closure:**

Title	Number	PI Name	Submission Type	Status	Continuing Review Date	Expiration Date
Evaluation of predictive and prognostic markers of breast cancer on serial samples: comparison between African-Americans and Non-African-Americans	5389	Garcia, Agustin	Initial	Approved	June 28, 2025	June 28, 2028

- **Inspections/Ongoing Oversight**

  There were no updates or issues to report from EH&S at this time.

1:18pm **IBC Registrations & Amendments for Review**

- **Applications and amendments determined by the Chair or IBC Coordinator that do not fall under the NIH Guidelines for FCR**
  - **New Protocols**

IBC #9368	Clinical Evaluation of the Panther Fusion M. gen Res Assay in Urogenital Specimens
PI Name	Taylor, Stephanie
Project Overview	This study aims to evaluate the clinical performance, reproducibility, and repeatability of the Panther Fusion M. gen Res Assay for detecting macrolide resistance mutations in *Mycoplasma genitalium*. The assay is a real-time PCR-based IVD test used on the fully automated Panther Fusion system. It will be tested on vaginal and endocervical swabs from females, and urine, urethral, and meatal swabs from males. All work will be conducted under BSL-2 conditions in accordance with LSUHSC safety protocols.
NIH Guidelines Section(s)	N/A
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves and lab coats or disposable gowns.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk • BioSafety Training: Shipping Biological Materials
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative	N/A

review (if applicable)	
Biosafety Level Assignment	BSL-2
IACUC status (if applicable)	N/A
IBC Vote	The IBC Chair determined that the application met all necessary requirements and was approved through designated member review (DMR). FCR was not required.

- **Amendments and Renewals**

Title	Number	PI Name	Submission Type	Expiration Date	Amendment Description
Role of oxidative stress in alcohol-induced bone resorption	5000	Ronis, Martin	Amended	Sep 28, 2026	Change in Personnel
Cell-specific Lipid Mediators Necessary for RPE Cell Survival	4494	Bazan, Nicolas	Amended	May 12, 2028	Change in Personnel
Molecular Profiling and Biomarker Discovery	5033	Adamec, Jiri	Amended	February 09, 2028	Change in Personnel
Sex Specific Effects of Adolescent Alcohol Exposure on BNST Plasticity	4027	Wills, Tiffany	Amended	January 20, 2026	Change in personnel
Stereotactic injection of 6HODA and Preformed alpha-synuclein fibrils for Parkinson's model	7462	Bazan, Nicolas	Amended	September 06, 2029	Change in Personnel
Long-Term Effects of Adolescent Alcohol on Pain	8651	Gilpin, Nicholas	Amended	May 26, 2030	Change in Personnel
Mechanisms of Immune Response Evasion and Resistance in Prostate, Breast, Colon and Kidney Tumors.	7527	Zea, Arnold	Amended	July 29, 2029	Change in Personnel
Use of V.A.C. VERAFLO to Deliver Pro-Healing and Anti-Infective Agents in an Acute Porcine Model of Surgical Wounds	4915	Smith, Alison	Amended	February 06, 2028	Change in Personnel
The Effects of Alcohol on Wound Healing in Murine MRSA-Infected Excisional Wound Model	6477	Smith, Alison	Amended	December 05, 2028	Change in Personnel

Interaction of Shisa proteins with GABA(A) receptor function	6694	Winsauer, Peter	Amended	February 15, 2029	Change in Personnel
Biomechanical comparison between Bioabsorbable, Magnesium, and Stainless-Steel Screws in the execution of periacetabular osteotomies.	7456	Clement, Rutledge	Amended	July 16, 2029	Change in Personnel
Diciphering the anti-inflammatory effects of serotonin 5-HT2A receptor activation	7500	Nichols, Charles	Renewed	July 16, 2029	
Role of host immune response and factors affecting resistance/susceptibility in the immunopathogenesis of Candida vaginitis	7592	Fidel, Paul	Renewed	July 27, 2029	
Exploratory Investigation of Respiratory and Cardiovascular Health Outcomes, Life Expectancy, and Cancer Diagnoses in Louisiana (EPA-WIRP Study)	7596	Katner, Adrienne	Renewed	July 26, 2029	
Brain reward and stress system interactions in alcohol dependence	4487	Avegno, Elizabeth	Renewed	June 20, 2027	
Tissue repository for rare cancers	2521	Skill, Nicholas	Renewed	August 03, 2026	
HER3-PHF8 signaling axis in triple-negative breast cancer progression	4528	Liu, Bolin	Renewed	August 10, 2027	
Role of Neuropeptides in Stress-Induced Escalation of Alcohol Drinking	4457	Gilpin, Nicholas	Renewed	August 15, 2027	
Alcohol-Cannabinoid System Interactions in the Context of Pain and AUD	7403	Edwards, Scott	Renewed	Jul 10, 2029	
Mouse Colony Maintenance and Breeding Plan	7677	Shen, Qiang	Renewed	Aug 21, 2029	

Signaling for Cell Survival	5213	Bazan, Nicolas	Renewed/Amended	July 14, 2028	Change in Personnel
The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection	7010	Cameron, Jennifer	Renewed/Amended	June 05, 2029	Change in Personnel
Effects of StellaLife Oral Care Recovery Kit on Palatal Wound Healing After Free Gingival Graft	5494	Joshi, Vinayak	Renewed/Amended	July 13, 2028	Change in Personnel
Effects of Lipids on Antibiotic Inhibition of Select Bacteria	4526	Hong, Song	Renewed/Amended	July 24, 2027	Change in Personnel

- **Applications reviewed and Suspended (in Grace Period) by the Chair after modifications requested by FCR. Continuing IBC oversight is required with annual reviews.**

  N/A

- **Full Committee Review of applications subject to *NIH Guidelines and our Policies*. Continuing IBC oversight required.**

IBC #8878	**Targeting Triple Negative Breast Cancer With Virotherapy**
PI Name	Hossain, Fokhrul
Project Overview	This study focuses on developing novel therapeutic strategies for Triple-Negative Breast Cancer (TNBC), a clinically aggressive subtype associated with high recurrence and mortality rates. The project targets the Notch and TGF-β signaling pathways, which are implicated in the survival and emergence of cancer stem-like cells (CSCs) following treatment. Due to systemic toxicity associated with current inhibitors, the proposed approach involves localized inhibition using recombinant adeno-associated virus vectors encoding soluble decoys of the TGF-β and Notch receptors. The main objectives are to evaluate the therapeutic potential of these r-AAV vectors and the VC2 virus in modulating the TNBC tumor microenvironment in vivo. All work will be conducted in accordance with BSL-2 containment procedures.
NIH Guidelines Section(s)	III-D-1-a III-D-4-b III-F-8 Appx C-VII
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.

Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-2
IACUC status (if applicable)	N/A
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA). • Votes: 7/7 for MRSA • COI: None reported Following a duly called vote of the committee, Dr. Hossain's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer.
IBC #7427	**Targeting Triple-Negative Breast cancer**
PI Name	Hossain, Fokhrul
Project Overview	This project aims to develop multi-targeted therapies for triple-negative breast cancer (TNBC), an aggressive subtype with limited treatment options and poor prognosis. The study focuses on three therapeutic strategies: (1) using Sulindac, a gamma-secretase modulator (GSM), to inhibit Notch signaling and reduce tumor growth, both alone and in combination with chemotherapy and immunotherapy; (2) evaluating novel PDE10A inhibitors (e.g., ADT-030) for their anti-tumor efficacy; and (3) targeting cancer stem cells through CD36 inhibition to disrupt lipid metabolism and limit tumor progression. These approaches seek to address the urgent need for effective, molecularly targeted therapies for TNBC. All work will be conducted under BSL-2 containment conditions.
NIH Guidelines Section(s)	III-D-4-b III-D-1-a III-F-8 Appx C-II
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative	N/A

review (if applicable)	
Biosafety Level Assignment	BSL-2
IACUC status (if applicable)	N/A
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA). • Votes: 7/7 for MRSA • COI: None reported Following a duly called vote of the committee, Dr. Hossain's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer. *Curran left the meeting, quorum remained with 7 committee members
IBC #9373	**Lipid Nanoparticles for Gene Editing to Correct Cystic Fibrosis in Mice and Rabbits**
PI Name	Wang, Guoshun
Project Overview	This study aims to develop and optimize lipid nanoparticles (LNPs) for efficient delivery of gene-editing complexes to correct cystic fibrosis (CF). The project will focus on optimizing lipid formulations and gene-editing payloads to improve correction efficiency. This approach has the potential to provide a long-term therapeutic strategy for CF and may be adaptable to other genetic or acquired diseases. All work will be conducted under BSL-2 containment conditions.
NIH Guidelines Section(s)	III-D-4-b III-F-1 III-F-2 III-F-4 III-F-5
Risk Assessment & Discussion	Personnel will utilize appropriate PPE, including gloves, lab coats or disposable gowns, and surgical masks. Work will be conducted in both a chemical fume hood and a certified BSL-2 biosafety cabinet, as appropriate. The research involves defective lentiviral vectors and known oncogenes and will be conducted following BSL-2 containment procedures. All biological waste will be collected in designated containers treated with bleach, and laboratory surfaces and equipment will be disinfected with 70% ethanol after each experiment.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-2

IACUC status (if applicable)	Approved
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA). Votes: 7/7 for MRSA COI: None reported Following a duly called vote of the committee, Dr. Wang's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer.
IBC #9322	**Molecular Drivers of HPV-Mediated Dysplasia Progression 2025**
PI Name	Cameron, Jennifer
Project Overview	This project seeks to identify and characterize the cellular signaling pathways that determine whether HPV-associated epithelial dysplasia resolves or progresses to severe disease and cancer. Using in vitro cell-culture models, investigators will examine virus-derived components (without use of infectious virus) to uncover molecular drivers of dysplasia severity. Insights from these studies are expected to guide the development of novel therapeutic strategies to interrupt HPV-mediated progression and prevent malignancy.
NIH Guidelines Section(s)	III-F-8 Appx C-II III-E III-F-5
Risk Assessment & Discussion	Personnel working in the laboratory will use appropriate personal protective equipment (PPE), including gloves, lab coats or disposable gowns, head covers, and surgical masks. All work involving biohazardous materials will be conducted within a certified Class II biosafety cabinet (BSL-2 rated) to ensure proper containment and minimize exposure risk.
Training	All institutional trainings required are complete for lab staff listed in the registration: • COI in Research • Laboratory Safety • IBC Compliance • BBP High Risk
EH&S Assessment	The lab was inspected, and no deficiencies were found.
Occupational Health Representative review (if applicable)	N/A
Biosafety Level Assignment	BSL-2 ABSL-2
IACUC status (if applicable)	N/A
IBC Vote	The Primary Reviewer made a motion to assign the determination of Modifications Required to Secure Approval (MRSA) • Votes: 7/7 • COI: None reported

	Following a duly called vote of the committee, Dr. Cameron's protocol was conditionally approved, pending submission and approval of the requested revisions by the Primary Reviewer.

2:06pm **Adjournment**

The IBC Chair moved to adjourn the meeting at 2:06PM. The next meeting is scheduled for Wednesday, August 13, 2025, via Zoom.